Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis' Menactra Demonstrates Noninferiority To Menomune, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The meningococcal vaccine Menactra met its primary safety endpoint of noninferiority in severe systemic adverse events. Sanofi-Aventis failed to show lot consistency within predefined equivalence limits, FDA says.

You may also be interested in...



Sanofi-Aventis' Menactra Post-Approval Commitments Should Include Long-Term Safety, Efficacy Data

The quadravalent meningococcal conjugate vaccine displayed immunogenicity and safety similar to Menomune, an FDA Advisory Committee says. Sanofi-Aventis says that preliminary results from a three-year follow-up study suggest that Menactra patients have longer antibody persistence than Menomune.

Sanofi-Aventis' Menactra Post-Approval Commitments Should Include Long-Term Safety, Efficacy Data

The quadravalent meningococcal conjugate vaccine displayed immunogenicity and safety similar to Menomune, an FDA Advisory Committee says. Sanofi-Aventis says that preliminary results from a three-year follow-up study suggest that Menactra patients have longer antibody persistence than Menomune.

Aventis/VaxGen AIDS Vaccine Phase III Update Will Be Heard By Advisory Committee Sept. 23

FDA's Vaccines & Related Biologics Advisory Committee will discuss ongoing study of Aventis' ALVAC vCP-1521 HIV vaccine with VaxGen's AIDSVAX. The committee will review Aventis' meningococcal conjugate vaccine Menactra Sept. 22.

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel